We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Molecular Data Inc | NASDAQ:MKD | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.41 | 0.42 | 0.4639 | 0 | 01:00:00 |
Fourth Quarter and Fiscal Year 2019 Financial Highlights
Fourth Quarter and Fiscal Year 2019 Operational Updates
______________1 “GMV” refers to gross merchandise value of the transaction orders placed by customers under the direct sales model or the gross merchandise value of the transaction orders the Company facilitates between customers and suppliers under the marketplace model during the specified period; under the direct sales model, the GMV does not include discounts or returns by the customers and may include the shipping fees in some cases; under the marketplace model, the GMV does not include shipping fees or discounts, regardless of whether the chemicals are actually delivered or returned.
Management Comments
“2019 was a landmark year for us, highlighted by our IPO on the Nasdaq Stock Market, on December 30, 2019, which created immediate and increased brand awareness to new users, customers and partners,” said Dr. Dongliang Chang, Founder of the Company and Chairman of the Board. “We finished 2019 strong with a number of operational and financial achievements across the board. To continue our growth momentum in 2020, our strategies focus on expanding our user base, strengthening customer engagement and retention, as well as further observing and meeting our customers’ evolving and diverse needs along the entire chemical value chain.”
“We are pleased to see solid progress with growth across each of our core business segments in 2019. It is worth noting that net revenues from our marketplace model and online membership service both achieved three-digit year-over-year growth,” commented Dr. Zheng Wang, Chief Executive Officer and Director of the Company. “With the increasing need of chemical industry participants to improve their operational efficiencies, the steady growth of the chemical industry, and an increasing internet penetration of the chemical e-commerce market, we believe our comprehensive and sophisticated chemical knowledge engine and business intelligence capabilities, our one-stop comprehensive suite of services, and our innovative big data and AI technologies, place us in an ideal position to further our leadership position in the sector. As we move through 2020, we will continue to invest in our knowledge engine and other technologies while looking forward to further growing our GMV, diversifying our value-added services and expanding global presence.
“With respect to the COVID-19 pandemic, since its outbreak, many business operations in China were halted and factories were temporarily closed for a period of time, which would negatively affect our overall financial results in the first quarter of 2020. Depending on the global progression of the outbreak, our ability to obtain chemicals and deliver chemicals to customers may be partly or completely disrupted not only in our Chinese facilities but globally. However, at the same time, we observed increased online traffic on our platform in early 2020 during the outbreak, compared to the same period in 2019, especially from overseas customers and suppliers, which is also in line with our business strategy this year. We are also actively promoting our financial services to customers and suppliers on our platform to address potential financial needs during the outbreak. We believe that we can effectively cope with the dynamics caused by the outbreak and will continue to closely monitor the evolving situation,” Dr. Wang concluded.
“We are pleased with our strong financial results for both the fourth quarter and fiscal year 2019, achieving outstanding revenue growth while narrowing net loss. Our balance sheet has also been maintained at a healthy level,” said Mr. Zhaohong Li, Chief Financial Officer of the Company. “With a goal to extend our solid growth trend in 2020, we look forward to further improving our results of operation with an emphasis on margin expansion and operational efficiencies improvement.”
Fourth Quarter 2019 Financial Results
Net Revenues
Net revenues were RMB4,101.2 million (US$589.1 million), a 38.1% increase from RMB2,969.6 million in the same period of 2018. The increase was primarily attributable to the steady increase in the number of users on the platform.
Cost of Revenues
Cost of revenues was RMB4,063.8 million (US$583.7 million), a 38.4% increase from RMB2,935.9 million in the same period of 2018. This change was primarily due to the increase in net revenues.
Gross Profit and Gross Margin
Gross profit was RMB37.4 million (US$5.4 million), a 10.8% increase from RMB33.7 million in the same period of 2018. Gross margin decreased to 0.9%, compared with 1.1% in the same period of 2018. The decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.
Operating Expenses
Total operating expenses were RMB93.7 million (US$13.5 million), a 52.5% decrease from RMB197.5 million in the same period of 2018. The decrease was primarily due to the reduction of expenses associated with share-based compensation in the fourth quarter of 2019 compared to the same period in 2018.
Operating Loss
Operating loss was RMB56.4 million (US$8.1 million), compared with RMB163.8 million in the same period of 2018.
Net Loss
Net loss was RMB58.1 million (US$8.3 million), compared with RMB166.6 million in the same period of 2018.
Fiscal Year 2019 Financial Results
Net Revenues
Net revenues were RMB13.2 billion (US$1,902.6 million), a 46.3% increase from RMB9.1 billion in fiscal year 2018. The increase was primarily attributable to the Company’s efforts to diversify product offerings and an increase in overall GMV.
Cost of Revenues
Cost of revenues was RMB13.1 billion (US$1,887.8 million), a 46.5% increase from RMB9.0 billion in fiscal year 2018. This change was primarily due to the increase in the purchase volume of chemicals, which was in line with the net revenues growth.
Gross Profit and Gross Margin
Gross profit was RMB103.0 million (US$14.8 million), a 28.5% increase from RMB80.2 million in fiscal year 2018. Gross margin decreased to 0.8%, compared with 0.9% in fiscal year 2018. The slight decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.
Operating Expenses
Total operating expenses were RMB293.0 million (US$42.1 million), a 7.3% decrease from RMB316.0 million in fiscal year 2018.
Operating Loss
Operating loss was RMB190.0 million (US$27.3 million), compared with RMB235.8 million in fiscal year 2018.
Net Loss
Net loss was RMB191.3 million (US$27.5 million), compared with RMB254.6 million in fiscal year 2018.
Certain Balance Sheet Item
As of December 31, 2019, the Company had cash, cash equivalents and restricted cash of RMB57.7 million (US$8.3 million), compared to RMB6.5 million as of December 31, 2018.
Conference Call
The Company’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on March 25, 2020 (8:00 AM Beijing/Hong Kong time on March 26, 2020).
Dial-in details for the earnings conference call are as follows:
United States: | +1-866-519-4004 |
International: | +65-6713-5090 |
Hong Kong: | 800-906-601 |
Mainland China: | 400-620-8038 |
Conference ID: | 6679446 |
A telephone replay will be available two hours after the call until April 8, 2020 by dialing:
United States: | +1-855-452-5696 |
International: | +61-2-8199-0299 |
Replay Access Code: | 6679446 |
Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://investor.molbase.com/.
About Molecular Data Inc.
Molecular Data Inc. is a leading technology-driven platform in China’s chemical industry, connecting participants along the chemical value chain through integrated solutions. The Company delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and SaaS suite that are intended to solve pain points for participants in the traditional chemical industry. Built upon a comprehensive knowledge engine and artificial intelligence (AI) capabilities, the Company’s e-commerce solutions are mainly offered through its online platform, consisting of molbase.com, molbase.cn, Moku Data Weixin account, Chemical Community App and other ancillary platforms.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.9618 to US$1.00, the rate in effect as of December 31, 2019 published by the Federal Reserve Board.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue” or other similar expressions. Among other things, the Outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a variety of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, results of operations and financial condition; the expected growth of the education market; the Company’s ability to monetize the user base; fluctuations in general economic and business conditions in China; the potential impact of the COVID-19 to the Company’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Molecular Data Inc.Eva MaTel: +86-400-6021-666E-mail: investor@molbase.com
The Piacente Group, Inc.Emilie WuTel: +86-21-6039-8363E-mail: molbase@tpg-ir.com
In the United States:
The Piacente Group, Inc. Brandi PiacenteTel: +1-212-481-2050E-mail: molbase@tpg-ir.com
Source: Molbase
MOLECULAR DATA INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands of RMB and US$) | ||||||||||
As of December 31, | ||||||||||
2018 | 2019 | |||||||||
(RMB’000) | (RMB’000) | (USD’000) | ||||||||
Unaudited | ||||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | 6,477 | 5,156 | 741 | |||||||
Restricted cash | - | 52,518 | 7,544 | |||||||
Accounts receivable, net | 40,730 | 20,424 | 2,934 | |||||||
Unbilled receivables | 12,813 | 106,060 | 15,235 | |||||||
Notes receivable | 2,075 | 124,176 | 17,837 | |||||||
Inventories, net | 7,256 | 4,351 | 625 | |||||||
Amounts due from related parties | 2,366 | 828 | 119 | |||||||
Prepayments and other current assets | 295,985 | 215,125 | 30,900 | |||||||
Total current assets | 367,702 | 528,638 | 75,935 | |||||||
Non-current assets: | ||||||||||
Property and equipment, net | 1,762 | 1,106 | 159 | |||||||
Intangible assets, net | 2,134 | 1,560 | 224 | |||||||
Operating lease right-of-use assets | - | 3,219 | 462 | |||||||
Total non-current assets | 3,896 | 5,885 | 845 | |||||||
Total assets | 371,598 | 534,523 | 76,780 | |||||||
Liabilities and Shareholders’ Deficit | ||||||||||
Current liabilities: | ||||||||||
Short-term borrowings | 82 | 13,749 | 1,975 | |||||||
Accounts payable | 49,315 | 338,941 | 48,686 | |||||||
Deferred revenue | 153,467 | 107,181 | 15,396 | |||||||
Accrued expenses and other liabilities | 24,709 | 108,034 | 15,518 | |||||||
Operating lease liabilities-current | - | 3,080 | 442 | |||||||
Amount due to related parties-current | 27,844 | 143,958 | 20,678 | |||||||
Income taxes payable | - | 352 | 51 | |||||||
Total current liabilities | 255,417 | 715,295 | 102,746 | |||||||
Non-current liabilities: | ||||||||||
Amounts due to related parties-non-current | 177,776 | 33,453 | 4,805 | |||||||
Deferred government grants | 30 | - | - | |||||||
Total non-current liabilities | 177,806 | 33,453 | 4,805 | |||||||
Total liabilities | 433,223 | 748,748 | 107,551 | |||||||
Shareholders’ deficit | ||||||||||
Ordinary shares | 98 | 98 | 14 | |||||||
Additional paid-in capital | 498,626 | 537,618 | 77,223 | |||||||
Accumulated other comprehensive loss | - | (316 | ) | (45 | ) | |||||
Accumulated deficits | (560,349 | ) | (751,625 | ) | (107,963 | ) | ||||
Total shareholders’ deficit | (61,625 | ) | (214,225 | ) | (30,771 | ) | ||||
Total liabilities and shareholders' deficit | 371,598 | 534,523 | 76,780 |
MOLECULAR DATA INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME(Amounts in thousands of RMB and US$, except for number of shares and per share data) | |||||||||||||
Quarter Ended | Year Ended | ||||||||||||
December 31, 2018 | December 31, 2019 | December 31, 2019 | December 31, 2018 | December 31, 2019 | December 31 2019 | ||||||||
(RMB'000) | (RMB'000) | (USD'000) | (RMB'000) | (RMB'000) | (USD'000) | ||||||||
Unaudited | Unaudited | ||||||||||||
Total net revenues | 2,969,580 | 4,101,200 | 589,101 | 9,053,266 | 13,245,839 | 1,902,646 | |||||||
Chemical Trading – direct sales model | 2,964,556 | 4,079,854 | 586,035 | 9,045,458 | 13,206,243 | 1,896,958 | |||||||
Chemical Trading – marketplace model | 3,270 | 15,596 | 2,240 | 4,387 | 26,513 | 3,808 | |||||||
Online membership service | 1,754 | 3,740 | 537 | 3,421 | 10,650 | 1,530 | |||||||
Financial service | - | 494 | 71 | - | 917 | 132 | |||||||
Others | - | 1,516 | 218 | - | 1,516 | 218 | |||||||
Cost of revenues | (2,935,863 | ) | (4,063,842 | ) | (583,734 | ) | (8,973,097 | ) | (13,142,828 | ) | (1,887,849 | ) | |
Gross profit | 33,717 | 37,358 | 5,367 | 80,169 | 103,011 | 14,797 | |||||||
Operating expenses: | |||||||||||||
Sales and marketing expenses | (50,280 | ) | (25,689 | ) | (3,690 | ) | (103,293 | ) | (108,858 | ) | (15,636 | ) | |
General and administrative expenses | (133,079 | ) | (26,354 | ) | (3,786 | ) | (173,872 | ) | (104,471 | ) | (15,006 | ) | |
Research and development expenses | (17,159 | ) | (14,535 | ) | (2,088 | ) | (36,889 | ) | (45,038 | ) | (6,469 | ) | |
Reversal/(Allowance) for doubtful accounts | 3,036 | (27,137 | ) | (3,898 | ) | (1,907 | ) | (34,618 | ) | (4,973 | ) | ||
Total operating expenses | (197,482 | ) | (93,715 | ) | (13,462 | ) | (315,961 | ) | (292,985 | ) | (42,084 | ) | |
Operating loss | (163,765 | ) | (56,357 | ) | (8,095 | ) | (235,792 | ) | (189,974 | ) | (27,287 | ) | |
Interest expenses, net | (3,942 | ) | (2,193 | ) | (315 | ) | (19,049 | ) | (4,368 | ) | (627 | ) | |
Foreign exchange (loss)/gain | (9 | ) | 12 | 2 | (3,033 | ) | 185 | 27 | |||||
Other income, net | 838 | 914 | 132 | 3,235 | 3,311 | 475 | |||||||
Loss before income tax | (166,878 | ) | (57,624 | ) | (8,276 | ) | (254,639 | ) | (190,846 | ) | (27,412 | ) | |
Income tax benefits/(expenses) | 277 | (430 | ) | (62 | ) | - | (430 | ) | (62 | ) | |||
Net loss | (166,601 | ) | (58,054 | ) | (8,338 | ) | (254,639 | ) | (191,276 | ) | (27,474 | ) | |
Net loss attributable to Molecular Data Inc. | (166,601 | ) | (58,054 | ) | (8,338 | ) | (254,639 | ) | (191,276 | ) | (27,474 | ) | |
Loss per share: | |||||||||||||
Basic and diluted | (0.54 | ) | (0.19 | ) | (0.03 | ) | (0.82 | ) | (0.62 | ) | (0.09 | ) | |
Weighted average shares outstanding | |||||||||||||
Basic and diluted | 310,627,024 | 310,627,024 | 310,627,024 | 310,627,024 | 310,627,024 | 310,627,024 | |||||||
Other comprehensive income, net of tax of nil | - | - | - | - | - | - | |||||||
Comprehensive loss | (166,601 | ) | (58,054 | ) | (8,338 | ) | (254,639 | ) | (191,276 | ) | (27,474 | ) | |
Comprehensive loss attributable to Molecular Data Inc. | (166,601 | ) | (58,054 | ) | (8,338 | ) | (254,639 | ) | (191,276 | ) | (27,474 | ) |
1 Year Molecular Data Chart |
1 Month Molecular Data Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions